ArticleExperimental and therapeutic medicine2018
Regulatory effect of immunosuppressive agents in mice with renal ischemia reperfusion injury.
Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- Impact of ischemia duration on MRI-derived perfusion parameters in a mouse kidney transplant model.European radiology experimental · 2026Article
- Evaluation of renal cold ischemia-reperfusion injury with intravoxel incoherent motion diffusion-weighted imaging and blood oxygenation level-dependent MRI in a rat model.Frontiers in physiology · 2023Article
- The clinical significance of receiving a kidney allograft from deceased donor with chronic histologic changes.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Polyphenols and Novel Insights Into Post-kidney Transplant Complications and Cardiovascular Disease: A Narrative Review.Frontiers in cardiovascular medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was designed to investigate the regulatory effect of rapamycin in mice with renal ischemia-reperfusion injury. A total of 100 mice were randomly divided into normal control, sham operation, model and experimental groups with 25 rats in each group. Mice in the experimental group were subjected to rapamycin gavage. Mice in each group were sacrificed 24 h after operation. Then, blood, spleen and left kidney were collected. PAS staining was used for semi-quantitative analysis of renal pathological injury. Serum creatinine (SCr) and blood urea nitrogen (BUN) levels were measured. TUNEL method was used to detect cell apoptosis. Flow cytometry was used to detect the percentage of NKT cells. The expression of CXC chemokine ligand 10 (CXCL10), hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) mRNA were detected by RT-qPCR. Semi-quantitative scoring of renal pathological injury showed that pathological injury score of the experimental group was significantly lower than that of the model group (p<0.05). Serum levels of SCr and BUN in the experimental group was compared to those in the model group (p<0.05). The number of apoptotic cells in the experimental group was compared to that of the model group (p<0.05). The percentage of NKT cells in the experimental group was compared to that of the model group (p<0.05). The percentage of NKT cells was significantly higher in the kidney and peripheral blood of the experimental group than that in the model group (p<0.05). The expression levels of HIF-1α and VEGF mRNA in the model and experimental groups were significantly lower in the experimental group than those in the model group (p<0.05). The expression levels of CXCL10 mRNA in the model and experimental groups were significantly higher in the experimental group than those in the model group (p<0.05). The results indicated that rapamycin can significantly upregulate the expression level of CXCL9 and promote the accumulation of NKT cells in kidney from spleen through peripheral blood. Rapamycin can also inhibit the HIF-1α expression level and protect renal ischemia-reperfusion injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.